RadNet, Inc. — FY 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing also reports fourth-quarter results; it is an annual report, not a standalone Q4 filing. Figures are in U.S. dollars.
Business context
RadNet operates freestanding outpatient diagnostic imaging centers and related radiology businesses, including PACS software and teleradiology. At year-end it operated 300 centers in seven states, up from 259 a year earlier, and performed 5.64 million imaging procedures. Growth included acquisitions and joint-venture activity.
Key financial metrics
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Net revenue | $809.6 million | $717.6 million |
| Income from operations | $39.1 million | $53.3 million |
| Net income attributable to RadNet common stockholders | $7.7 million; $0.17 diluted EPS | $1.4 million; $0.03 diluted EPS |
| Adjusted EBITDA (non-GAAP) | $121.7 million | $126.5 million |
| Cash from operating activities | $67.0 million | $61.0 million |
| Cash and cash equivalents at year-end | $0.45 million | $0.31 million |
| Working capital at year-end | $72.9 million | $58.7 million |
| Total debt obligations at year-end | $640.7 million | $597.6 million |
Revenue rose 12.8%, while procedures increased 16.8%. Operating income was about 4.8% of net revenue, down from about 7.4%; net income attributable to RadNet was about 1.0% of revenue. Cash used in investing was $96.8 million, including $90.8 million for facility acquisitions and $43.0 million for property and equipment, partly offset by sale proceeds. The company reported $72.9 million of working capital but very little cash on hand. Its $101.25 million revolving facility was undrawn at year-end.
Fourth-quarter net revenue was $215.7 million versus $185.6 million in Q4 2014. Net income attributable to RadNet was $0.9 million, or $0.02 per diluted share, compared with $4.2 million, or $0.10 per diluted share, in Q4 2014.
Material changes versus prior year
- Net revenue increased $92.1 million. Comparable centers’ net service-fee revenue rose 1.7%; acquisitions added substantially to reported growth.
- Capitation revenue increased 28.0% to $98.9 million, or 11.7% of net revenue. Management noted that these arrangements transfer utilization risk to RadNet and its contracted practices.
- Bad-debt provision rose 20.9% to $36.0 million, or 4.3% of net revenue, from 4.0%. Accounts receivable increased to $162.8 million from $148.2 million.
- Operating costs rose 17.5% to $708.3 million, faster than revenue. Management cited acquired operations, staffing and volume, supplies, outside services, equipment maintenance and RIS-system rollout costs.
- Operating income declined despite revenue growth. Attributable net income increased, aided in part by the absence of 2014’s $15.9 million debt-extinguishment loss and by 2015’s $5.4 million gain on imaging-center sales.
- RadNet acquired 43 centers and closed or sold three, for a net increase of 41. It sold ten New Jersey centers to a 49%-owned joint venture for $35.5 million and recorded a $5.4 million gain.
Outlook, risks and unusual items
- No numerical company financial guidance is provided in the filing. Management said cash from operations, available cash and borrowing capacity were expected to meet short-term liquidity needs, while noting future financing needs depend on conditions and factors outside its control.
- Management cited industry demand drivers including an aging population and broader use of imaging, while identifying reimbursement pressure, competition, weather seasonality and high-deductible plans as risks. First-quarter volumes and revenue are typically lowest.
- Debt is substantial and largely secured; term loans carry variable rates, include restrictive covenants and have significant scheduled maturities, including in 2018. RadNet reported covenant compliance at year-end. It warned that interest-rate increases, refinancing constraints or covenant breaches could impair liquidity and operations.
- The filing identifies dependence on physician referrals and contracted radiology groups, capitation utilization risk, acquisition integration, regulatory compliance, physician recruitment, and cybersecurity and information-system disruptions as material risks. The December 2015 strategic relationship with Imaging Advantage may not deliver anticipated benefits.
- Meaningful-use incentives contributed $3.3 million of 2015 income. The company also reported $7.6 million in stock-based compensation and a $5.4 million gain on center sales. Goodwill was $239.4 million; management reported no impairment from its 2015 test.
- Management concluded internal control over financial reporting was ineffective at year-end because of a material weakness in IT general controls and related manual controls affecting revenue and accounts receivable. Ernst & Young issued an adverse opinion on internal controls, but an unqualified opinion on the financial statements. Management described remediation plans involving system consolidation, access and change controls, and timely, sufficiently precise review of manual controls.
- Ordinary-course litigation was disclosed; management did not expect current matters to have a material adverse effect. The filing notes extensive healthcare regulatory exposure, including anti-kickback, self-referral, privacy, licensing and reimbursement requirements.
Most important facts for investors to verify
- Whether revenue and receivable control weaknesses are remediated, and whether subsequent filings report any restatement or further control deficiencies.
- Cash conversion and collection trends, including bad-debt expense, allowance levels, receivable aging and physician credentialing delays.
- Debt maturities, variable-rate exposure, covenant headroom and the company’s capacity to fund acquisitions, capital spending and debt service.
- How much future growth comes from acquired centers versus comparable-center performance, and whether operating margins and Adjusted EBITDA stabilize.
- Capitation contract profitability and utilization experience, and the realized benefits and risks of the Imaging Advantage relationship.
- The final purchase accounting for major acquisitions, including Diagnostic Imaging Group, and any subsequent impairment or contingent consideration changes.